Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Ralph Mocikat"'
Autor:
Ellen Brenner, Barbara F. Schörg, Fatima Ahmetlić, Thomas Wieder, Franz Joachim Hilke, Nadine Simon, Christopher Schroeder, German Demidov, Tanja Riedel, Birgit Fehrenbacher, Martin Schaller, Andrea Forschner, Thomas Eigentler, Heike Niessner, Tobias Sinnberg, Katharina S. Böhm, Nadine Hömberg, Heidi Braumüller, Daniel Dauch, Stefan Zwirner, Lars Zender, Dominik Sonanini, Albert Geishauser, Jürgen Bauer, Martin Eichner, Katja J. Jarick, Andreas Beilhack, Saskia Biskup, Dennis Döcker, Dirk Schadendorf, Leticia Quintanilla-Martinez, Bernd J. Pichler, Manfred Kneilling, Ralph Mocikat, Martin Röcken
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-19 (2020)
The growth of cancer cells can be stably arrested by cytokine-induced senescence. Here, the authors show that cancers with defects in senescence-inducing cell cycle regulator pathways are resistant to immune checkpoint blockade.
Externí odkaz:
https://doaj.org/article/ffeefb0c18174583b0c353a1c64a24f9
Publikováno v:
Translational Oncology, Vol 14, Iss 9, Pp 101170- (2021)
In malignant disease, CD4+Foxp3+ regulatory T cells (Tregs) hamper antitumor immune responses and may provide a target for immunotherapy. Although immune checkpoint blockade (ICB) has become an established therapy for several cancer entities includin
Externí odkaz:
https://doaj.org/article/c49efe5c27f249e588bbfc6e907c1d97
Autor:
Vera Bauer, Tanja Riedel, Ralph Mocikat, Fatima Ahmetlic, Josia Fauser, Carolin Flessner, Nadine Hömberg, Roman Hennel, Ellen Brenner, Kirsten Lauber
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 1 (2021)
Background Although antibodies blocking immune checkpoints have already been approved for clinical cancer treatment, the mechanisms involved are not yet completely elucidated. Here we used a λ-MYC transgenic model of endogenously growing B-cell lymp
Externí odkaz:
https://doaj.org/article/4259eb19d88447d2a363554ef982c306
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/28985bd175f04c9db8b4706438388a96
Publikováno v:
Molecular Medicine, Vol 19, Iss 1, Pp 54-61 (2013)
Abstract Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to recruit T cells toward antigens on the tumor cell surface and, moreover, to activate accessory cells through their immunoglobulin Fc region in
Externí odkaz:
https://doaj.org/article/08ec4f4b1668430db55894883c0eab70
Autor:
Niklas Muenchmeier, Sophia Boecker, Lorenz Bankel, Laura Hinz, Nicole Rieth, Constantin Lapa, Anna N Mendler, Elfriede Noessner, Ralph Mocikat, Peter J Nelson
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e72749 (2013)
BACKGROUND: Cellular therapy is a promising therapeutic strategy for malignant diseases. The efficacy of this therapy can be limited by poor infiltration of the tumor by immune effector cells. In particular, NK cell infiltration is often reduced rela
Externí odkaz:
https://doaj.org/article/a767ad6f616b48279f2d0cdeb9ac8030
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e25294 (2011)
gp350, the major envelope protein of Epstein-Barr-Virus, confers B-cell tropism to the virus by interacting with the B lineage marker CD21. Here we utilize gp350 to generate tailored exosomes with an identical tropism. These exosomes can be used for
Externí odkaz:
https://doaj.org/article/d6433e8d8ea249bab3d07391d6c34420
Autor:
Ralph Mocikat, Horst Lindhofer, Raymund Buhmann, Frauke Neff, Nina Eissler, Peter Ruf, Nina Deppisch
Trifunctional bispecific antibodies (trAb) are novel anticancer drugs that recruit and activate different types of immune effector cells at the targeted tumor. Thus, tumor cells are effectively eliminated and a long-lasting tumor-specific T-cell memo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::251f0d06a62bf4124467a82046de7771
https://doi.org/10.1158/1535-7163.c.6538330.v1
https://doi.org/10.1158/1535-7163.c.6538330.v1
Autor:
Ralph Mocikat, Horst Lindhofer, Raymund Buhmann, Frauke Neff, Nina Eissler, Peter Ruf, Nina Deppisch
Supplementary Figures S1-S4. Supplementary Figure S1. Development of anti-antibodies following Surek treatment; Supplementary Figure S2. Activation and proliferation of T cells after treatment with trAb Surek alone; Supplementary Figure S3. Weight lo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::023d321dc26b367a9ecbc369a4022d5d
https://doi.org/10.1158/1535-7163.22506214
https://doi.org/10.1158/1535-7163.22506214
Autor:
Ralph Mocikat, Martin Röcken, Stefan Stevanović, Tim Sparwasser, Albert Geishauser, Nico Trautwein, Vera Bauer, Nadine Hömberg, Tanja Riedel, Fatima Ahmetlić
Foxp3+ regulatory T cells (Tregs) sustain immune homeostasis and may contribute to immune escape in malignant disease. As a prerequisite for developing immunologic approaches in cancer therapy, it is necessary to understand the ontogeny and the antig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1b0eb7ba2c40a84b33e526999aa2d5f
https://doi.org/10.1158/2326-6066.c.6549085.v1
https://doi.org/10.1158/2326-6066.c.6549085.v1